The pharmacokinetics of intravenous salbutamol in pediatric status asthmaticus: a pilot study.

The pharmacokinetics of intravenous salbutamol in pediatric status asthmaticus: a pilot study. - The pharmacokinetics of intravenous salbutamol.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37955

Enrollment

Registered

2010-12-14

Start date

2011-09-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute severe asthma status asthmaticus

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Age 0 to 18 years-admitted to the hospital because of status asthmaticus- Need for continuous salbutamol nebulisation (more than 3 times/ hour)- Patient/parental informed consent

Exclusion criteria

Exclusion criteria: - Withdrawal of informed consent

Design outcomes

Primary

Measure	Time frame
The main study parameter is the description of the pharmacokinetic parameters of intravenous salbutamol.	—

Secondary

Measure	Time frame
Secondary study parameters are the efficacy (asthma scores) and safety (occurrence of side-effects) of intravenous salbutamol.	—

Countries

Netherlands

Outcome results